In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Angiogene (restenosis) raised $Cdn6mm in first round

Executive Summary

Angiogene Inc. (radiolabelled DNA for prevention of restenosis) raised $4.2mm (Cdn$6mm) in its first round of venture financing. Sofinov provided $Cdn4mm, and la Societe Innovatech du Grand Montreal provided an additional $Cdn2mm.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies